Press Release

Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer

by
Dalen Meeter

CFO Further Positions Company for Growth and Continued Advancement of Clinical Programs.

SAN DIEGO, April 30, 2025 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing personalized, autologous cell therapies, has appointed Dalen Meeter, CPA, MBA, as Chief Financial Officer (CFO).

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

by
image 7

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. has successfully completed dose escalation and the first two cohorts of patients in the ASPIRO study, an ANPD001 Phase 1/2a clinical trial in Parkinson’s Disease (PD). The Autologous-derived Study of a Parkinson’s Investigational Regenerative therapy in an Open-label trial (ASPIRO) was launched in 2024 to assess ANPD001 in … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson’s Disease

by
step 234 edited

Company is scaling out production of ANPD001 investigational cell therapy.

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. has advanced its plans for automating production of ANPD001, including a capacity expansion for autologous manufacturing at its San Diego-based GMP facility. ANPD001, an investigational cell therapy program for treating people with Parkinson’s disease (PD), is currently being studied in the company’s ASPIRO Phase 1/2a clinical trial.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at UBS Global Healthcare Conference

by
Aspen Kameel Farag IMG 7524 Final e1727705111641

SAN DIEGO, Nov. 12, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer Kameel Farag will present company updates in a fireside chat today at 4:15 pm PT at the UBS Global Healthcare Conference in Rancho Palos Verdes, Calif., where he will detail Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. The UBS Global Conference is designed to … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Collaboration and License Agreement with Cell X Technologies

by
Untitled design 19

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — Aspen Neuroscience has entered into a collaboration and license agreement with Cell X Technologies to advance Aspen’s plans for automating the iPSC stage of its autologous manufacturing platform. Aspen will leverage its established bioinformatics-based platform, and will lead all discovery, preclinical, development and commercialization activities associated with the advancement of automated manufacturing for … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Endpoints News Honors Aspen Neuroscience Co-Founder Dr. Jeanne Loring in “20 Women Breaking New Ground”

by
Untitled design 17

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ — EndPoints News has named Jeanne Loring, PhD, Aspen Neuroscience co-founder and senior advisor, a recipient of the 20 Women Breaking New Ground in BioPharma. The publication’s annual 2024 Women in BioPharma R&D Special Report recognizes the field’s most inspiring and driven women leaders. “Dr. Jeanne Loring is one of the earliest pioneers in human stem cell … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience to Showcase Advances in Autologous Cell Therapy Development at 2024 Cell & Gene Meeting on the Mesa

by
Untitled design 16 e1736137671761

SAN DIEGO and PHOENIX, Oct. 7, 2024 /PRNewswire/ — Presentations by Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D. and Chief Technology Officer Kim Raineri will highlight the latest therapeutic and corporate developments, at the annual Cell & Gene Meeting on the Mesa, held this week in Phoenix, Ariz. and live-streamed globally.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Expansion of Autologous Cell Therapy Manufacturing in San Diego

by
Aspen Neuro Manuf QC Team

Company Outlines Plans for Industrialization of Personalized Cell Therapy Manufacturing.

SAN DIEGO, Oct. 1, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing personalized (autologous) cell therapies, announced the expansion of its San Diego footprint near its headquarters in Torrey Pines, with a new 22,000 square foot facility for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell therapies.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at Upcoming Investor Conferences

by
Aspen Kameel Farag IMG 7524 Final e1727705111641

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer, Kameel Farag, will present this week at three biotechnology investor conferences, where he will provide company updates detailing Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

by
ClearPoint Filming Team

SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data from this cohort has been accepted for late breaking presentations this week at the MDS International Congress of Parkinson’s Disease and Movement Disorders, taking place in Philadelphia September 27 – October 1.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites per protocol under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo Reverse Horizontal RGB

Aspen Neuroscience leverages stem cell biology and advanced genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2026 Aspen Neuroscience - All Rights Reserved